Dalfampridine Tablet, Film Coated, Extended Release
Product Images NDC 67877-444

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Dalfampridine (NDC 67877-444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dalfampridine 10mg 60tab

Label for Dalfampridine 10 mg extended-release tablets by Ascend Laboratories, LLC. The label states the tablets contain 10 mg Dalfampridine each, with a package size of 60 tablets. It includes storage instructions, dispensing warnings, and notes the product is Rx only. Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, Parsippany, NJ.*

FDA Label Image

Dalfampridine-equa (Dalfampridine Equa)

A mathematical formula representing creatinine clearance (Crcl), calculated as (140 minus age) multiplied by weight in kilograms, divided by serum creatinine in mg/dL times 72. This formula is related to kidney function assessment commonly referenced in clinical settings.*

FDA Label Image

Dalfampridine-figure1 (Dalfampridine Figure1)

A bar graph showing the average percent increase in walking speed from baseline for patients receiving Dalfampridine Extended-release Tablets 10 mg b.i.d. compared to placebo. The x-axis represents different thresholds of walking speed increase, while the y-axis shows the percentage of patients. Bars indicate higher percentages for the Dalfampridine group compared to placebo at most thresholds, with p-values displayed for statistical comparisons.*

FDA Label Image

Dalfampridine-figure2 (Dalfampridine Figure2)

A bar graph comparing the percentage of patients achieving various thresholds of average percent increase in walking speed from baseline between placebo and Dalfampridine extended-release tablets 10 mg twice daily. The y-axis represents the percentage of patients, and the x-axis shows thresholds from 0% to 60% increase. P values for statistical comparisons between groups are included at each threshold.*

FDA Label Image

Dalfampridine-struc (Dalfampridine Struc)

Chemical structure diagram of dalfampridine showing a pyridine ring with an amino group (NH2) attached. This represents the active ingredient dalfampridine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.